Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential. On October 20, Raymond James initiated coverage on Taysha Gene Therapies with a Strong Buy rating and a $13 price target, aligning with the broader analyst consensus.
Pressmaster/Shutterstock.com
The firm cited promising Phase 1/2 REVEAL trial results for Rett syndrome and positive FDA feedback as key drivers. With a $1.28 billion market cap and a cash-rich balance sheet, Taysha is well-positioned to advance its clinical programs.
Recent milestones include Breakthrough Therapy Designation, FDA protocol alignment, and approval for a 6-month interim analysis that could fast-track regulatory submission. Patient enrollment for REVEAL Part B is underway, with final dosing expected by mid-2026 and potential commercialization in 2027. Taysha’s focus on a genetically defined Rett syndrome population offers a clear therapeutic opportunity.
Taysha Gene Therapies Inc. is a clinical-stage biotech firm dedicated to advancing adeno-associated virus (AAV)-based gene therapies for rare, single-gene disorders affecting the central nervous system. Its mission centers on delivering targeted treatments that address the root genetic causes of these conditions.
READ NEXT: Top 10 Stocks to Buy As Gold Rallies and 13 Stocks to Buy According to Billionaire Ray Dalio’s Bridgewater Associates.
This article is originally published at Insider Monkey.
